AI
Commented by Fabian Lorenz on October 29th, 2025 | 07:25 CET
BIG NEWS at Nordex! OpenAI fuels the AI energy boom! Siemens Energy and dividend stock RE Royalties benefit
Good news for the energy sector. OpenAI is calling on the US government to expand its energy infrastructure. Siemens Energy owes its 1,000% rally to the AI boom. However, analysts are cautioning ahead of the next quarterly results. Another hidden gem in the energy sector is RE Royalties. The Canadian company primarily finances renewable energy projects across North America, combining steady growth with an attractive dividend yield of over 10%. The CEO recently detailed the firm's strategy in an interview. It is not entirely clear where Nordex's sudden growth is coming from. In any case, the stock market is celebrating the forecast upgrade.
Read
Commented by Fabian Lorenz on October 28th, 2025 | 07:15 CET
Better than BioNTech, Evotec & Co.? BioNxt Solutions faces key milestones and is considering an AI takeover – Stock in an upward trend
An exciting alternative to Evotec, BioNTech, and similar companies is BioNxt Solutions. The Canadian-German company's business model is a refreshing departure from traditional biotech companies with their huge research costs. BioNxt reformulates already approved active ingredients. For instance, Ozempic is set to be taken orally instead of by injection in the future. The sublingual cladribine formulation for multiple sclerosis is already well advanced, with its preclinical phase nearing completion. At the same time, CEO Hugh Rogers is considering an acquisition in the field of artificial intelligence to further accelerate development processes. The aforementioned development in the billion-dollar obesity market is also exciting. If a breakthrough succeeds, the Company could soon become a takeover candidate for Big Pharma.
Read
Commented by Fabian Lorenz on October 24th, 2025 | 07:25 CEST
Yesterday +16%! D-Wave explodes again! Siemens Energy and First Hydrogen shares benefit from AI's energy hunger
What a bounce for D-Wave. After a sharp correction yesterday, the quantum stock rose 16%. Is the Trump administration getting involved in quantum companies? That is the rumor making the rounds. Meanwhile, the energy hunger of AI data centers is also keeping the stock market on tenterhooks. One beneficiary from Germany is Siemens Energy. The stock is running like clockwork. Small modular reactors (SMRs) are a huge topic in North America. The Canadian government is providing massive support to industry, which should benefit First Hydrogen. The Company plans to combine its hydrogen expertise with SMR technology. So - buy now?
Read
Commented by Carsten Mainitz on October 23rd, 2025 | 07:25 CEST
AI hidden gem NetraMark Holdings is poised for a price surge, TeamViewer crash, and Novo Nordisk supervisory board resigns! What to do?
Artificial intelligence (AI) is widely regarded as a key technology with enormous potential across all industries. The use of AI opens up new opportunities, particularly in the biotechnology and pharmaceutical industries: from faster identification of potential active ingredients to more precise diagnostics and the automation of complex laboratory processes. Companies that make targeted use of AI gain competitive advantages in a highly competitive environment. Following a broad-based bull market, it is worth exploring promising second-tier players.
Read
Commented by André Will-Laudien on October 21st, 2025 | 07:45 CEST
AI boom and DAX fireworks! Another 100% with NetraMark, Bayer, and Novo Nordisk
Savvy investors are already taking notice! Artificial intelligence is revolutionizing drug research and radically reducing development costs. Algorithms are discovering molecular patterns that even the most experienced researchers would overlook, thus accelerating the path from laboratory to patient. Whether in oncology, rare diseases, or metabolic disorders, big data-driven models now enable more precise drug predictions and more realistic simulations of clinical outcomes. Those who understand AI can profit handsomely from the next biotech boom. You just have to muster the courage to finally get involved!
Read
Commented by Armin Schulz on October 17th, 2025 | 07:05 CEST
Three stocks, one trend: Jump on the momentum bandwagon with Almonty Industries, AMD, and ASML
The stock market often rewards those who recognize a trend before it becomes mainstream. This is not about short-term speculation, but about identifying companies with strong fundamental tailwinds that can drive prices higher over the long term. This momentum is fueled by structural factors: global technology shifts, geopolitical realignments, and the reorganization of critical supply chains. There is a reason why the saying goes: Go with the flow! Almonty Industries, AMD, and ASML each embody these powerful forces and currently have strong momentum on their side. Let's take a closer look.
Read
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read
Commented by Nico Popp on October 16th, 2025 | 07:00 CEST
Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech
Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.
Read
Commented by Fabian Lorenz on October 15th, 2025 | 08:35 CEST
BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!
The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?
Read
Commented by André Will-Laudien on October 13th, 2025 | 07:15 CEST
Trump tariffs 3.0 for China and the Bitcoin crash: Major movements at Strategy, Metaplanet, Coinbase, Nakiki, and D-Wave
With Donald Trump's announcement of a new 100% tariff measure against China on Friday afternoon, previously strong performers in the crypto sector came under significant pressure. The protagonists, Strategy, Coinbase, and Metaplanet, were hit with daily losses of between 3 and 10%. D-Wave, which had gained over 50% in the last 6 weeks, is also starting to feel the squeeze. Nakiki shares, on the other hand, reacted with price gains. The German Bitcoin stock can be pleased that its coin purchase program doesn't start until November - this could offer attractive buying opportunities, with the timing looking ideal. However, it remains to be seen whether this move will trigger a broader correction accompanied by rising volatility. Meanwhile, precious metals have recently been moving in only one direction: up! Could the rally now make an abrupt return?
Read